MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research to evaluate a number of intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Principal trial aims were being To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis patients, when one of https://devinyrjgx.thechapblog.com/30300189/about-brd4-inhibitor-27